Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06528301 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 8 to 9 Eligibility criteria expanded, about 17 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 17 words
  2. Site details revised at 2 of 8 sitesv11
  3. Eligibility criteria shortened, about 2 wordsv10 See this version in full on ClinicalTrials.gov ↗
  4. Site details revised at 2 of 8 sitesv9
  5. Study sites: 6 to 8v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 4 to 6 Primary and study completion dates: Apr 2029 to Mar 2029 · Start date changed from estimate of Mar 2025 to Mar 10, 2025v7 Show 2 more changesShow less
    • Primary and study completion dates: Apr 2029 to Mar 2029
    • Start date changed from estimate of Mar 2025 to Mar 10, 2025
  2. Study sites: 3 to 4 Start date: Feb 2025 to Mar 2025v6 Show 1 more changeShow less
    • Start date: Feb 2025 to Mar 2025
  3. Site contacts updated at 1 of 3 sitesv5
  4. Start date: Dec 2024 to Feb 2025 Study sites: 2 to 3v4 Show 1 more changeShow less
    • Study sites: 2 to 3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Primary and study completion dates: Mar 2029 to Apr 2029 · Start date: Nov 2024 to Dec 2024v3 Show 3 more changesShow less
    • Study sites: 0 to 2
    • Primary and study completion dates: Mar 2029 to Apr 2029
    • Start date: Nov 2024 to Dec 2024
  6. Study title shortened, about 1 wordv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Umoja Biopharma
3 trials monitored
See all monitored trials
Leukemia
2,566 trials monitored
See 143 trials at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
DLBCL
650 trials monitored
See 38 trials at risk
and 1 more disease
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
Trial Details
NCT Number NCT06528301
Lead Sponsor Umoja Biopharma
Conditions Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)
Enrollment 106 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov